Morphological characteristics of lateral pelvic lymph nodes in locally advanced lower rectal cancer: A retrospective study

局部晚期低位直肠癌侧盆腔淋巴结形态学特征:一项回顾性研究

阅读:1

Abstract

AIM: This study aimed to investigate the potential of the size and aspect ratio of metastatic and non-metastatic lateral pelvic lymph nodes (LPLNs) as low-risk markers for locally advanced lower rectal cancer, without treatment by neoadjuvant chemoradiation therapy or LPLN dissection. METHODS: This single-center, retrospective cohort study evaluated 310 consecutive patients diagnosed with lower rectal cancer (T: T3/T4, N: any, and M: M0) who underwent curative surgery without neoadjuvant therapies between 2010 and 2018. The harvested LPLNs were categorized into groups A (metastasis-positive lymph nodes), B (metastasis-negative lymph nodes in the area bearing metastasis-positive lymph nodes), C (metastasis-negative lymph nodes in a metastasis-negative area in metastasis-positive patients), and D (lymph nodes in non-metastatic patients). The main outcome measure was the relationship among lymph node size, aspect ratio, and metastasis in the LPLNs. RESULTS: Overall, 3962 LPLNs were harvested. The long and short axes and the aspect ratio were significantly longer and higher, respectively, in group A than in the other groups (P < .001). The aspect ratio in group B was significantly higher than that in groups C and D (P < .001). The aspect ratio in group C was significantly higher than that in group D (P < .001). Furthermore, no metastasis-positive lymph nodes had an aspect ratio of less than 0.4. Metastasis-positive LPLNs tended to be larger and rounder than their metastasis-negative counterparts. CONCLUSIONS: Metastatic LPLNs in patients with lower rectal cancer are significantly larger and have a higher aspect ratio. Lymph nodes with aspect ratios of <0.4 were metastasis negative.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。